Acceleron Announces Pricing of Public Offering of Common Stock
22 Enero 2014 - 9:30PM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel protein therapeutics for cancer and rare
diseases, today announced the pricing of a public offering of
2,400,000 shares of common stock at a public offering price of
$50.00 per share, before underwriting discounts. In addition,
Acceleron has granted the underwriters a 30-day option to purchase
up to an additional 360,000 shares of common stock at the public
offering price, less underwriting discounts. The offering is
expected to close on or about January 28, 2014, subject to
satisfaction of customary closing conditions.
Citigroup and Leerink Partners LLC are acting as joint
book-running managers for the offering. Piper Jaffray & Co. is
acting as lead manager and JMP Securities is acting as co-manager
for the offering.
A registration statement on form S-1 relating to these
securities was declared effective on January 22, 2014. The offering
will be made only by means of a prospectus, copies of which may be
obtained from Citigroup, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY, 11717, or by email at
batprospectusdept@citi.com, or by phone at 800-831-9146; or Leerink
Partners LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA, 02110, or by email at
Syndicate@Leerink.com, or by phone at 800-808-7525.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
protein therapeutics for cancer and rare diseases. The company is a
leader in understanding the biology of the TGF-β protein
superfamily, a large and diverse group of molecules that are key
regulators in the growth and repair of tissues throughout the human
body, and in targeting these pathways to develop important new
medicines. Acceleron has built a highly productive R&D platform
that has generated innovative clinical and preclinical protein
therapeutic candidates with novel mechanisms of action. These
protein therapeutic candidates have the potential to significantly
improve clinical outcomes for patients with cancer and rare
diseases.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements,
including statements relating to the anticipated closing of the
underwritten public offering. Such forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those expressed or implied in such
statements. Applicable risks and uncertainties include those
identified under the heading “Risk Factors” included in the
prospectus related to the offering, and in other filings that the
Company may make with the SEC in the future. The forward-looking
statements contained in this press release reflect the Company’s
current views with respect to future events, and the Company does
not undertake and specifically disclaims any obligation to update
any forward-looking statements.
Acceleron PharmaKevin F. McLaughlin, 617-649-9204Senior Vice
President and Chief Financial OfficerorMedia contact:Suda
Communications LLCMaureen L. Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024